Tolerogenic antigen-presenting cells
CA 2480751 A1 · Owner: Revivicor Holdings, Inc. · Inventors: Innes, Donald Alan James; Moore, Marilyn Jean; Leishman, Andrew James
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been found that dendritic cells can be prepared which cannot mature. These cells can provide signal (1) to T cells but cannot provide costimulatory signal (2). T cells which are stimulated by the permanently immature dendritic cells therefore anergise so the dendritic cells are , tolerogenic rather than immunogenic. The cells are generally CD40-ve CD80-ve , and CD86-ve, and remain so when stimulated by inflammatory mediators such as lipopolysaccharide. The cells can be prepared conveniently by the culturing adherent embryonic stem cells in the presence of GM-CSF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.